Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
2008
2009
2010
Announcements
Articles
Articles and Publications
Campaign
Case Studies
Charge Capture and Pricing
Coding Integrity
Company
Consulting
Craneware Insights Articles
Education
Home
Journey
News & Events
Opportunities
Other
post
Press Releases
Products
Services
Testimonial
Trade Shows
Uncategorized
Uncategorized
Upcoming Events
Value Cycle
Webinars
White Papers

Have there been recent coding changes related to Pfizer COVID-19 vaccines?

Yes. On January 3, 2022, the FDA updated the emergency use authorization for the Pfizer pediatric COVID-19 vaccine (orange cap) to allow for third doses for certain immunocompromised children ages 5 through 11. It is important to highlight these are not booster doses – rather a third dosage of the vaccine for patients who meet certain clinical criteria. Additional information as to which pediatric patients qualify for a third dose can be found in the products emergency use authorization linked below. Administration of third doses will be reported with new CPT code 0073A, which CMS has confirmed will be retroactively effective back to January 3, 2022. The vaccine product itself will continue to be reported with CPT 91307. We have provided the long descriptions for both codes below for your convenience.

0073A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose

91307: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use

In addition to the update noted above, on January 3, 2022, the FDA also approved a new pre-diluted formulation of the Pfizer COVID-19 vaccine for patients 12 years and older. This product (which is packaged with a grey cap) and its associated administration services will be reported with the CPT codes noted below. CMS has confirmed that these codes will also be retroactively effective back to January 3, 2022.

91305: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, trissucrose formulation, for intramuscular use

0051A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose

0052A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose

0053A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose
0054A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose

We remind providers that per CMS directive, if you receive a COVID-19 vaccine product free of charge, you should only bill for the administration services and not the drug products themselves. For providers whose systems require a product code to bill for the administration, a token charge of $0.01 may be reported for the drug product.

Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization:
https://www.fda.gov/media/150386/download

CMS COVID-19 Vaccines and Monoclonal Antibodies Homepage:
https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-monoclonal-antibodies

AMA press release, “AMA announces CPT update for third dose of Pfizer’s pediatric COVID-19 vaccine”:
https://www.ama-assn.org/press-center/press-releases/ama-announces-cpt-update-third-dose-pfizer-s-pediatric-covid-19-vaccine

CDC, “Pfizer-BioNTech COVID-19 Vaccine (Gray Cap) Age 12 and Over”:
https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/bioNTech-gray-cap-12-and-over.html

Skip to toolbar